



Patents & IP Sequences | Clinical Trials | Drug Pipelines


Creating IP Reports with BizInt Smart Charts: Tips & Tricks

PIUG 2017 Annual Conference, Atlanta GA

John Willmore, Vice-President
21 May 2017

www.bizint.com

BizInt HQ has moved to the Seattle area!



Bossa earns her AKC agility championship



Agenda

- New content
- Integrating data with Reference Rows
- Updating reports
- Summary Records
- Your questions

Agenda

- New content
- Integrating data with Reference Rows
- Updating reports
- Summary Records
- Your questions



BizInt Smart Charts



for Patents

Patent Databases

Provide data on patents filed worldwide

- STN Classic & New
- Questel Orbit.com (incl FULLPAT)
- Minesoft PatBase
- Innovation, Cortellis IP, Integrity Patents
- LexisNexis TotalPatent
- GQ Life Sciences LifeQuest

Orbit.com: Improved Family Status table and Key Content

Tialo		Family S	tatus		Object of lowerties	Advantages / Describes lies
Title	Pub No.	State	Status	Expiry	Object of Invention	Advantages / Drawbacks
Engineering and optimization of	WO201493635A1	DEAD	LAPSED	2015-06-12	[0009] In one aspect, the invention	These are advantageous as when
improved systems, methods and	WO201493635A1	ALIVE	PENDING	2033-12-12	provides methods for using one or	singly mutated they provide
enzyme compositions for	US20140186919A1	ALIVE	PENDING			nickase activity and when both
sequence manipulation	US8865406B2	ALIVE	GRANTED	2033-12-12	system.	mutations are present the Cas9 is
	US8889418B2	ALIVE	GRANTED	2033-12-12	[0011] Also provided are uses of	converted into a catalytically null
	US20140335620A1	ALIVE \	GRANTED	2033-12-12	the present sequences, vectors,	mutant which is useful for generic
	EP2898075A1	ALIVE \	GRANTED	2033-12-12	enzymes or systems, in medicine.	DNA binding.
	JP2016501532A	ALIVE \	PENDING	2033-12-12	Also provided are the same for use	
	AU2013359212A1	ALIVE	PENDING	2033-12-12	in gene or genome editing. Also provided is use of the same in	terms Cas and CR ISPR enzyme
	IL239315A	ALIVE	PENDING 2033-12-12		the manufacture of a medicament	are general!)? [CONT.]
	SG11201504519TA	ALIVE	PENDING	2033-12-12	fugene or genome editing, for	
	KR20150105634A	ALIVE	PENDING	2033-12-12	instance treatment by gene or	
	CN105209621A	ALIVE	PENDING	2033-12-12	genome editing. [CONT.]	
	HK1207119A1	ALIVE	GRANTED	2033-12-12	generic causing. [corr]	
Crispr/cas-related methods and	WO2015138510A1	ALIVE	PENDING	2035-03-10	In another aspect, disclosed	Unilateral subretinal injections of
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (Ica10)	US20150252358A1	ALIVE	PENDING	2035-03-10	herein is a nucleic acid, e.g., an	adeno-associated virus particles
					isolated or nonnaturally occurring nucleic acid, e.g., DNA, that comprises (a) a sequence that encodes a gRNA molecule comprising a targeting domain that	carrying constructs encoding the wild-type RPE65 cDNA were shown to be safe and moderately effective in some patients, without causing any adverse effects.

Family Status table (including Kind Code)

Key Content

Orbit.com: FULLPAT support including top line legal status

FULLPAT: fullpat_sample

	Title	Questal Family ID	Pater	ıt Famil	ly		Status De	tails	
	ride	Questel Family ID	Patent	Kind	Date	Pub No.	State	Status	Expiry
	Methods and compositions for	74634926	WO2016187159	A2	2016-11-24	WO 2016187159 A2	ALIVE	PENDING	2018-11-15
1	target detection in a nanopore using a labelled polymer scaffold		WO2016187159	A3	2016-12-29				
	Delivery system for functional	68771523	US20150071906	A1	2015-03-12	US 9526784 B2	ALIVE	GRANTED	2034-08-18
2	nucleases		US9526784	B2	2016-12-27				
	Efficient non-meiotic allele	68723127	US20150067898	A1	2015-03-05	US 9528124 B2	ALIVE	GRANTED	2034-10-09
3	introgression		US9528124	B2	2016-12-27				
4	Cell cycle dependent genome regulation and modification	74986865	WO2016210271	A1	2016-12-29	WO 2016210271 A1	ALIVE	PENDING	2018-12-24

Status Details table (like Family Status)

PatBase: Support for Dead/Alive flags

	PatBase: patbase_da_tags						
	Title	tus	Stata				
	Title	Patent	Kind	Date	Pub No.	State	State
П	Gyroscopic space ship/station	WO 9819911	A2	1998-05-14	WO 9819911 A2	ALIVE	ALIVE
Ш	with docking mechanism	WO 9819911	A3	1998-07-09	WO 9819911 A3	ALIVE	
Ш		US 6045094	Α	2000-04-04	US 6045094 A	DEAD	
	1	CA 2268724	AA	2000-10-14	CA 2268724 AA	DEAD	
Ш		CA 2268724	С	2007-10-30	CA 2268724 C	DEAD	
Ш		JP 2001524044	T2	2001-11-27	JP 2001524044 T2	DEAD	
		JP 4026840	B2	2007-12-26	JP 4026840 B2	ALIVE	
Г	De-orbit instrument package	CA 2365758	AA	2002-06-20	CA 2365758 AA	DEAD	ALIVE
Ш		US 2002109047	Α	2002-08-15	US 2002109047 A	ALIVE	
l :	2	US 2004124313	Α	2004-07-01	US 2004124313 A	ALIVE	
		US 6869048	BB	2005-03-22	US 6869048 BB	ALIVE	
	SYSTEM WHEREIN INDIVIDUAL CAN VIEW LANDSCAPE OF TRAVEL/LANDSCAPE OF TRAVEL TO SPACE SUCH AS SPACE OBSERVATION/EARTH OBSERVATION/MARS IN REAL TIME ON INDIVIDUAL PERSONAL	JP 2006051945	A2	2006-02-23	JP 2006051945 A2	ALIVE	ALIVE

Family Status table (including Kind Code)

PatBase: selection of relevant claims

		Title	Patent	Family		Claims
		Title	Patent	Kind	Date	Claims
П		A METHOD FOR PRODUCING	AU 2014273082	AA	2014-12-04	WO14191518A1
		PRECISE DNA CLEAVAGE USING	WO 14191518	ÀΙ	2014-12-04	CLAIMS 1. A method for precisely
		CAS9 NICKASE ACTIVITY	CA2913865	AA	2015-11-27	inducing a nucleic acid cleavage in
						a genetic sequence in a cell
١,	1					comprising: (a) Selecting a first and second double-stranded
	١.					nucleic acid targets in said genetic
						sequence, each nucleic acid
						targets comprising, on one strand,
						a PAM motif at one 3' extremities;
						[CONT.]
		GENOME ENGINEERING	WO 15013583	A2	2015-01-29	US2015031132A
			WO 15013583	A8	2015-03-05	1. A method of altering target DNA
			WO 15013583	A3	2015-04-23	in a stem cell expressing a Cas 9 enzyme that forms a co-localization
			U3 2015031133	A	2015-01-29	complex with a guide RNA
			US 2015031132	Α	2015-01-29	complementary to the target DNA
١.	٦		AU 2014293015 CA 2918540	AA AA	2015-01-29 2016-01-15	and that cleaves the target DNA in
4	2		CA 29 18540	AA	2010-01-15	a site specific manner comprising
						(a) introducing into the stem cell a
						first foreign nucleic acid encoding
						the guide RNA complementary to
						the target DNA and which guides
						the enzyme to the [CONT.]
Н		METHODS FOR CORRECTING	WO 15089406	A1	2015-06-18	US9068179B
		CASPASE-9 POINT MUTATIONS	US 2015166985	Α	2015-06-18	1. A method of editing a nucleic
			US 2015166984	Α	2015-06-18	acid molecule encoding a
			US 2015166983	Α	2015-06-18	Presenilin1 (PSEN1) protein, the
			US 2015166982	Α	2015-06-18	method comprising contacting the
	3		US 2015166981	Α	2015-06-18	nucleic acid molecule with (a) a
•	۱,		US 2015166980	A	2015-06-18	fusion protein comprising a nuclease-inactive Cas9 domain
			U3 201516505 4	Α	2015-06-18	and a deaminase domain; and (b)
			US 9068179	В	2015-06-30	a single guide RNA (sgRNA)
						targeting the fusion protein of (a) to
						the PSEN1-encoding nucleic acid
						molecule; [CONT.]

PatBase & Orbit: Abstract and Claims source document identified

	Title	Database	Paten	t Famil	y	Abstract	Claims
	Title	Database	Patent	Kind	Date	ADSTRACT	Cidiffis
1	PROCESSED EDIBLE PRODUCT COMPRISING A POLYELECTROLYTE COMPLEX AND AN ANTIMICROBIAL COMPOUND	PatBase	WO 15034360	A1	2015-03-12	Source: WO15034360A1 The invention related to a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation. The invention further relates to a method for producing a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation, ICONT1	WO15034360A1 Claims 1. A processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation.
2	Method and system for controlling a cutting torch	FAMPAT	WO 201182492 US 20130221585 US 9011758	A1 A1 B2	2011-07-14 2013-08-29 2015-04-21	(WO201182492) A system for controlling a temperature of a flame of a torch for cutting a piece of material, comprising: a valve system fluidly connectable to an oxygen source and a fuel source for receiving a heating oxygen flow and a fuel flow, respectively, and the torch for propagating the heating oxygen and fuel flows thereto, the valve system comprising at least a first adjustable valve and [CONT.]	(WO201182492) 1. Asystem for controlling a temperature of a flame of a torch for cutting a piece of material, comprising: a valve system fluidly connectable to an oxygen source and a fuel source for receiving a heating oxygen flow and a fuel flow, respectively, and the torch for propagating the heating oxygen and fuel flows thereto, the valve system comprising at least a first adjustable valve [CONT.]



BizInt Smart Charts



for Patents

Literature Databases

Provide data on technical and scientific publications

- Biomedical (Embase, Biosis, Medline)
- Scientific (SciSearch, Chemical Abstracts, PQSciTech, etc)
- Technical (INSPEC, RAPRA, GEOREF, etc.)
- Hosts: STN (Classic & New),
 ProQuest Dialog, Ovid, PubMed



BizInt Smart Charts



for Patents

IP Sequence Databases

Provide data on sequences filed in patents

- GQ Life Sciences GenomeQuest (Geneseq, GQ-PAT)
- STN (USGENE, DGENE, PCTGEN)

Agenda

- New content
- Integrating data with Reference Rows
- Updating reports
- Summary Records
- Your questions


Using Reference Rows - unique content

	Database		Family	/ Status		Droboble Appignes
	Database	Pub No.	State	Status	Expiry	Probable Assignee
٠	Derwent World Patents Index					
	Derwent World Patents Index					
٠	GQPAT Gold+ Proteins					
	GQPAT Gold+ Proteins					
•	PatBase					PRESIDENT AND FELLOWS OF HARVARD COLLEGE
		US 20140356956 A1	ALIVE	PENDING	2034-06-04	
Ri [.]		US 9267135 B2	ALIVE	GRANTED	2034-06-04	


Using Reference Rows - rankings

	Title	Detabase	Paten	t Family	
	Title	Database	Patent	Kind	Date
1 .1	Modulating expression of a target nucleic acide comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease null Cas9 protein	Derwent World Patents Index	US20140356959	A1	20141204
1	Altering a target nucleic acid in a cell involves		US20140356956	A1	20141204
.2	RNAs and Cas9 protein nickase co-localize to	Patents Index	WO2014197568	A2	20141211
	DNA target nucleic acid and nick the target		WO2014197568	A3	20150312
	nucleic acid resulting in adjacent nicks		CA2914638	A1	20141211
1 .3	RNA-Guided Transcriptional Regulation	GQPAT Gold+ Proteins	US20140356959		20141204
1 .4	RNA-Guided Transcriptional Regulation	GQPAT Gold+ Proteins	US20140356956		20141204
1	RNA-GUIDED TRANSCRIPTIONAL REGULATION	PatBase	US 2014356959	Α	2014-12-04
.5			US 2014356956	Α	2014-12-04
			AU 2014274939	AA	2014-12-11
			WO 14197568	A2	2014-12-11
			WO 14197568	A3	2015-03-12
			CA2914638	AA	2015-12-04
			KR 20160014036	Α	2016-02-05
1	RNA-Guided Transcriptional Regulation	FAMPAT	US 2014356956	A1	2014-12-04
.6			US 2014356959	A1	2014-12-04
			US 9267135	B2	2016-02-23

Using Reference Rows - column rules



Using Reference Rows - "Summarize" rule



Reference Rows integrated report

CAS-9 - GenomeQuest, PatBase, DWPI (new STN), FAMPAT

Action a cell by introducing into the cell a first foreign nucleic acid encoding guide RIA sequences complementary to DIA, and introducing into the cell a second foreign nucleic acid encoding a Cas protein nu			Betalana	Pate	nt Family	,		Fam	ily Status		Backable Assissa		Sequence I	Locations	S	
1		litie	Database	Patent	Kind	Date	Pub No.	State	Status	Expiry	Probable Assignee	Seq. ID Number	% Identity	Length	Location	
2. New bacteriophage comprises populucieotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a guide RNA includes	1.	acid in a cell by introducing into the cell a first foreign nucleic acid encoding guide RNA sequences complementary to DNA, and introducing into the cell a second foreign nucleic acid encoding a	1.2 GPATPRT link 1.3 Patbase link	WO2015077290	A2 2	0150528	A2 US	ALIVE			FELLOWS OF HARVARD	US20150140664-0001	100.00	1368	(not found by	1.2
Descripting polypeptide comprising nuclease module, and targeting module comprising quide RNA, for restricting growth of host cell, and for preparing antiseptic composition of a target nuclease and targeting module comprising nuclease module, and targeting module comprision nuclear nuclea acid not prepared to the cell a nuclear nuclear acid comprises providing to the cell a nuclea acid to the cell a nuclea n						1.1 DWPI				1.4 FAMPAT	-					
Polymocleotide Poly	2.							ALIVE	PENDING	2034-11-11	RADIANT GENOMICS INC					
of a target nucleic acid comprises providing to the cell a nuclease of the cell an unclease of the cell and th	0.00000	polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	2.2 DWPI 2.3 GPATPRT link 2.4 GPATPRT link 2.5 Patbase link			015-12-10	US 20150132263 A1 US	ALIVE ALIVE	PENDING	2034-11-11	2.5 Patbase	US20150353901-0002	100.00	1368	claim: 19; 20	2.4
the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease series of the cell a nuclease series and the cell a guide RNA including a 40 2014/274939 AA 2014-12-11	3.	of a target nucleic acid	3.2 DWPI	US 2014356956	A 20	014-12-04	20140356956 A1				FELLOWS OF HARVARD	US20140356959-0001	100.00	1368	(not found by	3.3
3.5 Pathase		including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease null Cas9 protein	3.3 GPATPRT link 3.4 GPATPRT link 3.5 Patbase link	WO 14197568 WO 14197568 CA 2914638	A2 20 A3 20 AA 20	014-12-11 015-03-12 015-12-04 016-02-05	03 9207 133 BZ	ALIVE	SIGNIED						probable disclosure (not found by	3.4

Reference Rows integrated report

CAS-9 - GenomeQuest, PatBase, DWPI (new STN), FAMPAT

	Title	Databas		Pate	nt Fam	ily		Fam	ily Status	
	ittle	Dalabas	<u> </u>	Patent	Kind	Date	Pub No.	State	Status	Expiry
1.	Modulating expression	1.1 DW	/PI	US 2014356959	Α	2014-12-04	US	ALIVE	PENDING	2034-06-04
	of a target nucleic acid comprises providing to	1.2 DW		US 2014356956	Α	2014-12-04	20140356956 A1			
	the cell a guide RNA			AU 2014274939	AA	2014-12-11	US 9267135 B2	ALIVE	GRANTED	2034-06-04
	including a		ATPRT link	WO 14197568	A2	2014-12-11				
	transcriptional activator or repressor		ATPRT link	WO 14197568	А3	2015-03-12		4		
	domain as a fusion	1.5 Pat	tbase link	CA 2914638	AA	2015-12-04				
	protein, and providing	1.6 FAI	MPAT link	KR 20160014036	Α	2016-02-05				
	to the cell a nuclease null Cas9 protein									
	1.1 DWPI	4				1.5 Patbase				1.6 FAMPAT
						TO THE REAL PROPERTY AND ADDRESS OF THE PARTY			DENIBING	broken ber and the second
2.	New teriophage comprises	2.1 DW	/PI	WO 15070193		2015-05-14	WO 201570193 A1	ALIVE	PENDING	2034-11-11
	polynucleotide	2.2 DW	/PI	US 2015132263	A	2015-05-14	US	ALIVE	PENDING	2034-11-11
	expressing RNA-directed	2.3 GP	ATPRT link	US 2015353901	Α	2015-12-10	20150132263 A1	/ LIVE	1 LINDING	2004 11 11
	DNA-binding	2.4 GP/	ATPRT link				US	ALIVE	PENDING	2034-11-11
	polypeptide comprising	2.5 Pat	tbase link				20150353901 A1			
	nuclease module, and targeting module		MPAT link							
	comprising guide RNA,									
	for restricting growth of									
	host cell, and for preparing antiseptic									
	composition									,
	2.1 DWPI					2.5 Patbase				2.6 FAMPAT


Agenda

- New content
- Integrating data with Reference Rows
- Updating reports
- Summary Records
- Your questions

Updating reports

- File | Update
- The "key" chart is your baseline your existing report, against which new data is compared
- Rows from the baseline are copied in order to the new chart... new records added at bottom... changed records remain in position from baseline chart.

Updating reports



Updating reports

	T.U.	D 04-4	Pater	nt Famil	ly	Priority D	ata	Applicati	ons
	Title	Row Status	Patent	Kind	Date	Number	Date	Application	Date
2	SUBMICRON NATAMYCIN PARTICLE	Added	WO 15044465 WO 15044465	A2 A3		EP20140167408 EP20140192514		WO2015EP50647 WO2015EP50647	2015-01-15 2015-01-15
3	COMPOSITION COMPRISING A PESTICIDAL TERPENE MIXTURE AND A FUNGICIDE	Updated	WO 14020109 AU 2013298562 CA 2880671 AR 091953 KR 20150041638	A1 AA AA AA A		EP20120179145 WO2013EP66178		W02013EP66178 AU20130298562 CA20132880671 AR2013P102729 KR20157004997	2013-08-01 2013-08-01 2013-08-01 2013-08-01 2013-08-01

Updating reports (family oriented)

- "Added" means this is a new family in this report
- "Updated" means the family was seen before but has new/changed information
- "Unchanged" means the family has not changed from the baseline

- "Added" means this is a new publication in this report
- "Updated" means the publication has been changed (typically added indexing)
- "Unchanged" means the publication has not changed from the baseline


But what can we tell about the invention?

Na	atamycin_Innovation_Updated	d				
	Title	Common Family	Row Status	Database	US Patent Number	Pate
1	Agricultural product used for e.g. controlling plant disease and treating fungal diseases caused by fungi such as Fusarium semitectum comprises polyene antifungal compound and antifungal compound from family of strobilurin fungicides	WO 2012117049	Unchanged	Thomson Innovation + DWPI	A1 US 9034792 B2	DSM IP DSM IN PROPE MANAG
2	Treating/preventing occurrence/recurrence of Clostridium difficile infection by administering composition comprising two purified bacterial populations comprising bacteria having 16S ribosomal RNA sequence identical to reference bacterium	US 20140199281	Unchange	Record on Publisher Wordsher Images Column Properties Row Properties Add Row Hide Row Move Row Hide Column Sort Statistics	ebsite Ctrl+ Ctrl+1	
	Processing biomass to produce e.g. feed products, antibiotics involves processing polysaccharide based biomass using e.g. pyrolysis, sonication to form processed material with low recalcitrance level followed by microbial conversion		Unchange	Highlight cells Highlight rows Cut Copy Paste	Ctrl+ Ctrl+Shft+ Ctrl+ Ctrl+ Ctrl+	·L ·X ·C

- Thomson Innovation natamycin & ic=A23 & PD>=2011
- At the publication level we see:

1	Α	В
1	Row Status	Count
2	Unchanged	241
3	Added	150

Send updated chart to Reference Rows



Statistics on the Summarized Row Status

4	А	В
1	Row Status	Count
2	Unchanged	93
3	Unchanged Added	43
4	Added Unchanged	1
5	Added	53
6	I	

N	Natamycin_Innovation_Updated							
	Title Common Far		Row Status	Patent Family			Patent Assignee	
	Tide	Common raining	NOW Status	Patent	Kind	Date	Patent Assignee	
149	Composition, useful for protecting product including food product, feed product, pharmaceutical product, cosmetic product and agricultural product against fungi, comprises polyene antifungal compound and lactoperoxidase system	Ť	Unchanged ##	WO 2014083048	A1	2014-06-05	DSM IP ASSETS BV	
149	Composition, useful for protecting product including food product, feed product, pharmaceutical product, cosmetic product and agricultural product against fungi, comprises polyene antifungal compound and lactoperoxidase system		Added ##	WO 2014083048 EP 2925167 US 20150282489 CN 104883912	A1 A1 A1 A	2014-06-05 2015-10-07 2015-10-08 2015-09-02	DSM INTELLECTUAL PROPERTY ASSETS MANAGE DSM IP ASSETS BV RAVENSBERG W J STARK J WEBER F J	
149	Composition, useful for protecting product including food product, feed product, pharmaceutical product, cosmetic product and agricultural product against fungi, comprises polyene antifungal compound and lactoperoxidase system		Added ###	WO 2014083048 EP 2925167 US 20150282489 CN 104883912	A1 A1 A1 A	2014-06-05 2015-10-07 2015-10-08 2015-09-02	DSM INTELLECTUAL PROPERTY ASSETS MANAGE DSM IP ASSETS BV RAVENSBERG W J STARK J WEBER F J	

Visualize results:

- Create subtable
- Summarize all values
- Export

Р	ub. Number	Row Status	
WO 2	014179204 A1	Unchanged	450.4
	0160095331 A1		153.1
EP 29	991504 A1	Added	153.3

WO 2015024751 A1	Unchanged	154.1
EP 3062626 B1	Added	154.2
EP 3062626 A1	Added	154.3

WO 2015034360 A1 Unchanged	155.1
US 20160213051 A1 Added	155.2
EP 3041367 A1 Added	155.3

Agenda

- New content
- Integrating data with Reference Rows
- Updating reports
- Summary Records
- Your questions

"Summary Record" export

1. Title: Modulating expression of a target nucleic acid comprises providing to the cell a guide

RNA including a transcriptional activator or repressor domain as a fusion protein, and

providing to the cell a nuclease null Cas9 protein

Database: Derwent World Patents Index

Derwent World Patents Index

GQPAT Gold+ Proteins **GQPAT Gold+ Proteins**

PatBase FAMPAT

Patent Family:	Patent	Kind	Date

US 2014356959 2014-12-04 2014-12-04 US 2014356956 A AU 2014274939 AA 2014-12-11 WO 14197568 2014-12-11 A2 2015-03-12 WO 14197568 A3 CA 2914638 AA 2015-12-04 KR 20160014036 2016-02-05 A

Probable Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Sequence Locations: Sea. ID Number % Identity Length Location

US20140356959-0001 100.00 1368 probable disclosure (not found by automated parsing)

US20140356956-0001 100.00 probable disclosure (not found by 1368

automated parsing)

Notes – please provide further detail on this...

Claims:

 A method of modulating expression of a target nucleic acid in a cell comprising providing to the cell a guide RNA complementary to the target nucleic acid sequence including a transcriptional activator or repressor domain as a fusion protein for modulating target nucleic acid expression in vivo providing to the cell a nuclease null Cas9 protein that interacts with the guide RNA and binds to the target nucleic acid sequence in a site specific manner wherein the guide RNA including the transcriptional activator or repressor domain as a fusion protein and the Cas9 protein co-localize to the target nucleic acid sequence and wherein the transcriptional activator or represent domain modulates expression of the target nucleic







BizInt Smart Charts



for Patents

New "Summary Record" export

	1.	1. Title: RNA-GUIDED TRANSCRIPTIONAL REGULATION							
	Database: PatBase GQPAT Gold+ Proteins GQPAT Gold+ Proteins								
		Patent Family:	Patent	Kind	Date				
			<u>US 2014356959</u>	4	2014-12-04				
			US 2014356956	4	2014-12-04				
			AU 2014274939	AΑ	2014-12-11				
			WO 14197568	42	2014-12-11				
				43	2015-03-12				
				ΔA	2015-12-04				
			KR 20160014036	4	2016-02-05				
	Probable Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE								
Organism Species: Streptococcus pyogenes									
	S	Sequence Summary:	Seq. ID Number		Location		% Identity	Le	ngth
			US20140356956-000		obable disclosure (not fou tomated parsing)	nd by	100.00	1368	1
			US20140356959-000		obable disclosure (not fou tomated parsing)	nd by	100.00	1368	
	Alig	ınment:							
		Q: 1			ITDEYKVPSKKFKVLGNTD				60
		S: 1			ITDEYKVPSKKFKVLGNTD				60
		Q: 61			YLQEIFSNEMAKVDDSFFH				120
ı		S: 61			YLQEIFSNEMAKVDDSFFH				120
		Q: 121			KLVDSTDKADLRLIYLALA				180
		S: 121	NIVDEVAYHEKYPTIY	HLRK	KLVDSTDKADLRLIYLALA	HMIKFRGHE	LI EGDLN PDN	NSD	180
		Q: 181	VDKLFIQLVQTYNQLE	EENP	INASGVDAKAILSARLSKS	RRLENLIAC	LPGEKKNGLE	GN	240



Agenda

- New content
- Integrating data with Reference Rows
- Updating reports
- Summary Records
- Your questions



Questions?

Don't forget to visit us in the exhibit hall to learn more!

www.bizint.com